CELL-EASY
SME
CELL-EASY
Description
Cell Easy is a Contract Development and Manufacturing Services organization (CDMO) with a dedicated focus on Cell Therapies.
Cell Easy offers a comprehensive suite of services, including process development, process scale-up, cGMP manufacturing, and analytical support for immune cells (engineered CAR-T, NK cells, and non-engineered cells) as well as adult stem cells (MSCs, iPSCs, and Exosomes).
Our company has achieved significant milestones, such as advancing programs to Phase 2, partnering with top 30 international pharmaceutical companies, transitioning from autologous to allogenic processes.
Cell Easy offers a comprehensive suite of services, including process development, process scale-up, cGMP manufacturing, and analytical support for immune cells (engineered CAR-T, NK cells, and non-engineered cells) as well as adult stem cells (MSCs, iPSCs, and Exosomes).
Our company has achieved significant milestones, such as advancing programs to Phase 2, partnering with top 30 international pharmaceutical companies, transitioning from autologous to allogenic processes.
Referent Contact
Alexis Delbaere
alexis.delbaere@cell-easy.com
Resources
CELL-EASY
Address
4BIS, AVENUE HUBERT CURIEN TOULOUSE
31110 Toulouse, France
31110 Toulouse, France
Contact
info@cell-easy.com
Description
Cell Easy is a Contract Development and Manufacturing Services organization (CDMO) with a dedicated focus on Cell Therapies.
Cell Easy offers a comprehensive suite of services, including process development, process scale-up, cGMP manufacturing, and analytical support for immune cells (engineered CAR-T, NK cells, and non-engineered cells) as well as adult stem cells (MSCs, iPSCs, and Exosomes).
Our company has achieved significant milestones, such as advancing programs to Phase 2, partnering with top 30 international pharmaceutical companies, transitioning from autologous to allogenic processes.
Cell Easy offers a comprehensive suite of services, including process development, process scale-up, cGMP manufacturing, and analytical support for immune cells (engineered CAR-T, NK cells, and non-engineered cells) as well as adult stem cells (MSCs, iPSCs, and Exosomes).
Our company has achieved significant milestones, such as advancing programs to Phase 2, partnering with top 30 international pharmaceutical companies, transitioning from autologous to allogenic processes.
Resources
Matchmaking
Connect with CELL-EASY
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways
TRL
Type of technology (OECD Definition)
-
Cell and tissue culture and engineering
